Original article. Cost-effectiveness of annual microalbuminuria screening in Thai diabetics

1. Klein R, Klein BE, Moss S, DeMets DL. Proteinuria in diabetes. Arch Intern Med. 1988; 148:181-6.10.1001/archinte.1988.00380010183019Search in Google Scholar

2. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998; 128:982-8.10.7326/0003-4819-128-12_Part_1-199806150-00004Search in Google Scholar

3. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006; 4:CD006257.10.1002/14651858.CD006257695664617054288Search in Google Scholar

4. Sakthong P, Tangphao O, Eiam-ong S, Kamolratanakul P, Supakankunti S, Himathongkam T, et al. Costeffectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria. Nephrology. 2001; 6:71-7.10.1046/j.1440-1797.2001.00036.xOpen DOISearch in Google Scholar

5. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, et al. The CARI guidelines. Costeffectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes. Nephrology. 2010; 15(Suppl 1): S195-203.10.1111/j.1440-1797.2010.01239.x20591027Search in Google Scholar

6. Rippin JD, Barnett AH, Bain SC. Cost-effective strategies in the prevention of diabetic nephropathy. Pharmacoeconomics. 2004; 22:9-28.10.2165/00019053-200422010-0000214720079Open DOISearch in Google Scholar

7. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63:225-32.10.1046/j.1523-1755.2003.00712.x12472787Open DOISearch in Google Scholar

8. Krairittichai U, Potisat S, Jongsareejit A, Sattaputh C. Accuracy of urine dipstick test for microalbuminuria in type 2 diabetes mellitus patients. J Med Assoc Thai. 2011; 94 Suppl 2:S6-10.Search in Google Scholar

9. Lepore G, Maglio ML, Nosari I, Dodesini AR, Trevisan R. Cost-effectiveness of two screening programs for microalbuminuria in type 2 diabetes. Diabetes Care. 2002; 25:2103-4.10.2337/diacare.25.11.210312401764Search in Google Scholar

10. United Nation Thailand. Thailand Info [internet] 2010 [cited 2011 Jun 18]. Available from: http://www.un.or.th/thailand.Search in Google Scholar

11. National Health Security Office. Annual report of Thai Universal Health Coverage Scheme 2009. Bangkok: Sahamitr Printing and Publishing; 2010.Search in Google Scholar

12. Zhang AH, Cheng LT, Zhu N, Sun LH, Wang T. Comparison of quality of life and causes of hospitalization between hemodialysis and peritoneal dialysis patients in China. Health Qual Life Outcomes. 2007; 5:49.10.1186/1477-7525-5-49198878817678543Search in Google Scholar

13. Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol. 2004; 15:3117-25.10.1097/01.ASN.0000146423.71226.0C15579515Search in Google Scholar

14. McIntosh A, Hutchinson A, Marshall S, Barnes D, Brown V, Hopper S, et al. Clinical guidelines and evidence review for type 2 diabetes. Renal disease: prevention and early management. Sheffield: ScHARR, University of Sheffield; 2002.10.1177/14746514020020041401Search in Google Scholar

15. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998; 13:397-409.10.2165/00019053-199813040-00003Open DOISearch in Google Scholar

16. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005; 143:89-99.10.7326/0003-4819-143-2-200507190-00007Search in Google Scholar

17. Ministry of Public Health, Thailand. Public health statistics 2010 [Internet] 2010 [cited 2011 Jun 18]. Available from: http://bps.ops.moph.go.th/Healthinformation/statistic53/statistic53.pdf.Search in Google Scholar

18. Groop PH, Thomas MC, Moran JL, Wad☐n J, Thorn LM, M☐kinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009; 58:1651-8.10.2337/db08-1543Open DOISearch in Google Scholar

19. Pratipanawatr T, Rawdaree P, Chetthakul T, Bunnag P, Ngarmukos C, Benjasuratwong Y, et al. Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death. J Med Assoc Thai. 2010; 93(Suppl 3):S12-20.Search in Google Scholar

20. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.Search in Google Scholar

21. Tongsiri S, Cairns J. Estimating population-based values for EQ-5D health states in Thailand. Value Health. 2011; 14:1142-5.10.1016/j.jval.2011.06.005Open DOISearch in Google Scholar

22. World Health Organization. Choosing interventions that are cost-effective (WHO-CHOICE): costeffectiveness thresholds [internet] 2005 [cited 2011 Aug 24]. Available from: http://www.who.int/choice/costs/CER_levels/en/index.html.Search in Google Scholar

23. The World Bank. GDP per capita (current US$) [internet] 2011 [cited 2012 Aug 24]. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.Search in Google Scholar

24. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17:2937-44.10.1681/ASN.2006040368Open DOISearch in Google Scholar

25. Thaweethamcharoen T, Sakulbumrungsil R, Vasuvattakul S, Nopmaneejumruslers C. Comparison of SF-6D, EQ-5D and VAS in hemodialysis Thai patients. Value Health. 2010; 13:A567.10.1016/S1098-3015(11)73384-8Open DOISearch in Google Scholar

26. Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health. 2008; 11:733-41.10.1111/j.1524-4733.2007.00308.x18194399Open DOISearch in Google Scholar

27. Thavorncharoensap M, Teerawattananon Y, Natanant S, Werayingyong P, Yothasamut J, Putchong C, et al. Assessing a societal value for a ceiling threshold in Thailand. Nonthaburi, Thailand: Health Intervention and Technology Assessment Program; 2009.Search in Google Scholar

28. Kessler R, Keusch G, Szucs TD, Wittenborn JS, Hoerger TJ, Brugger U, et al. Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. Swiss Med Wkly. 2012; 142: w13508.10.4414/smw.2012.1350822307760Search in Google Scholar

29. Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol. 1992; 3(4 Suppl): S111-9.10.1681/ASN.V34s1111457753Search in Google Scholar

30. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ. 1995; 311:1595-9.10.1136/bmj.311.7020.1595Search in Google Scholar

31. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant. 2008; 23:1216-23.10.1093/ndt/gfn082Search in Google Scholar

32. Palmer AJ, Chen R, Valentine WJ, Roze S, Bregman B, Mehin N, et al. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes Metab. 2006; 32:69-76.10.1016/S1262-3636(07)70249-5Open DOISearch in Google Scholar

33. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003; 290:3101-14.10.1001/jama.290.23.310114679273Search in Google Scholar

34. Howard K, White S, Salkeld G, McDonald S, Craig JC, Chadban S, et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value Health. 2010; 13:196-208.10.1111/j.1524-4733.2009.00668.x19878493Open DOISearch in Google Scholar

35. Kiberd BA, Jindal KK. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure? Mayo Clin Proc. 1999; 74:559-64.10.4065/74.6.55910377929Open DOISearch in Google Scholar

36. Golan L, Birkmeyer JD, Welch HG. The costeffectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999; 131:660-7.10.7326/0003-4819-131-9-199911020-0000510577328Search in Google Scholar